about the team
AriaVax, Inc. is structured by its operating philosophy. We have developed a streamlined organization to support scientific advancement with our proprietary small molecule adjuvant, which is supported and enhanced by our business development function. We take an adaptative approach to our company and business outlook. Realizing the benefits of a diverse experience basis, the changing market conditions and environment, we believe that our core structure allows us to be focused, nimble and efficient in achieving our scientific and business goals.
We have a cooperative environment, maintaining our respective functions while utilizing our collective experience to solve the challenges facing AriaVax. We utilize both functions early in our development process to ensure potential commercial application of our discoveries.
Our focus is to utilize our small molecule technology to providing a adjuvant platform that uniquily enhances immunogens.
President
Frank A. Robey, Founder and CEO
Currently, Dr. Frank A. Robey is acting as Chief Scientific Officer. He is the primary inventor of the patents forming the basis of the Company’s intellectual property platform and the DeadlockTM technology. This technology was developed during his 15 years as a senior investigator at the NIH in Bethesda, MD. As a government scientist, Dr. Robey has produced out-licensed technology resulting in FDA-approved injectable products. He has also been a consultant on protein chemistry and FDA regulatory issues to many leading US biotech companies, including Centocor and Genentech. Prior to his appointment at NIH, Dr. Robey spent over eight years at the Food and Drug Administration (FDA) where he held research positions in the Division of Bacterial Products, the vaccine branch of the FDA, and several lead positions formulating the Agency’s first responses to biotechnology, including products used to treat and diagnose AIDS. His knowledge of FDA processes and procedures are crucial to the Company’s ability to move drug candidates through the approval process quickly.
Business Development
Martin A. Malanoski, Director, Business Development
Martin was brought in to identify, develop and cultivate our commercial and strategic relationships. He is responsible for non-scientific operations, business development and marketing. Martin started his career as a strategic and benchmarking consultant for Fortune 500 clients. He then moved into implementation, process improvement, and reorganization for an international organization. Martin moved backed to the United States, to become the CFO of a highly leveraged diversified media company. Successfully selling the entity, he then became the CFO for a second media company and assisted in the sale of the entity to a PE firm. After the sale, he realized his goal and started his own successful commercial production company. He adapted his business model to take advantage of the structural shift in the graphics industry. He then started a second company, where he had no day to day operational responsibilities, and was looking for a new industry and challenge. His multidisciplined approach, unique skill sets, and perspectives will allow AriaVax to achieve its business goals.